[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335337-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335337-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-analysis-reveals-that-p4ha3-is-a-prognostic-and-diagnostic-gastric-cancer-biomarker-that-can-predict-immunotherapy-efficacy","Comprehensive analysis reveals that P4HA3 is a prognostic and diagnostic gastric cancer biomarker that can predict immunotherapy efficacy","","Comprehensive analysis using data from TCGA, TIMER, and additional databases evaluates P4HA3 as a biomarker in gastric cancer and its potential to predict immunotherapy response. Elevated P4HA3 expression is associated with adverse prognostic outcomes and correlates with immune infiltration patterns, immune infiltration markers, tumor mutational burden, microsatellite instability, immune and stromal scores, and immune checkpoint activity. Findings support P4HA3 as an immune-related prognostic and therapeutic target, suggesting clinical value for guiding immune-based antitumor strategies in gastric cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-analysis-reveals-that-p4ha3-is-a-prognostic-and-diagnostic-gastric-cancer-biomarker-that-can-predict-immunotherapy-efficacy/335337/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-analysis-reveals-that-p4ha3-is-a-prognostic-and-diagnostic-gastric-cancer-biomarker-that-can-predict-immunotherapy-efficacy/335337.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is P4HA3, and why is it studied in gastric cancer?","Question",{"text":63,"@type":64},"P4HA3 (prolyl 4-hydroxylase subunit alpha 3) is described as a factor involved in proliferation, invasion, and metastasis in multiple tumors, but its role in gastric cancer needed further clarification.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the results relate P4HA3 to prognosis in gastric cancer?",{"text":68,"@type":64},"Higher P4HA3 expression in gastric cancer is associated with worse prognostic outcomes, indicating prognostic value.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence connects P4HA3 to immunotherapy response?",{"text":72,"@type":64},"The analysis finds strong correlations between P4HA3 expression and immune infiltration cells, immune infiltration markers, TMB, MSI, immune/stromal scores, and immune checkpoints, supporting its potential as an immune-related predictive biomarker.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335337,1790132567,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nComprehensive analysis reveals that P4HA3 is a prognostic and diagnostic gastric cancer biomarker that can predict immunotherapy efficacy  \nYuanhang Yu1,2,4, Kexin Luo2,3,4, Meihan Liu1,2,4, Long Chen1,2, Xi Gao1,2, Lijuan Zhang1,2, Xianfu Li1,2􀀍 & Hongpan Zhang1,2􀀍  \nGastric cancer (GC) is one of the most challenging malignant tumors worldwide, primarily because of its high incidence and mortality rates. Prolyl 4-hydroxylase subunit alpha 3 (P4HA3) has been established as a pivotal factor for facilitating cell proliferation, invasion, and metastasis across multiple human tumors. Nevertheless, the precise role of P4HA3in GC has not been fully elucidated. In this study, we used data from The Cancer Genome Atlas (TCGA) to examine the role of P4HA3 as a potential biomarker for predicting immunotherapy response in patients with GC. Our comprehensive analysis of data from theTCGA, TIMER, and other databases revealed a significant association between elevated P4HA3 expression inGC and adverse prognostic outcomes. Furthermore, we confirmed that P4HA3 expression was strongly correlated with immune infiltrating cells, immune infiltration markers, the tumor mutational burden (TMB), microsatellite instability (MSI), the immune score, the stromal score, and immune checkpoints, thus highlighting P4HA3 as a crucial and dependable therapeutic target within the context of immune-based antitumor strategies. Our findings suggest that P4HA3 may function as an immune-related biomarker in the pathogenesis and treatment of GC, indicating that P4HA3 is a promising prognostic and therapeutic target for this malignancy.  \nKeywords P4HA3, Gastric cancer, Prognostic, Immunotherapy  \nGC ranks as the fifth most prevalent malignancy globally and is the fourth leading cause of cancer-related mortality1. GC typically presents with insidious onset, leading to the majority of patients being diagnosed at advanced stages, which results in suboptimal treatment outcomes and a significantly shortened median survival period2. Despite significant advancements in therapeutic approaches, the prognosis for patients with advanced gastric cancer remains bleak, with median survival times often ranging between 4 and 12 months3. Recent advancements in immunotherapy – particularly the emergence of checkpoint inhibitors, such as nivolumaband pembrolizumab – have improved clinical outcomes in a subset of patients with GC4,5. The KEYNOTE-062 study demonstrated that pembrolizumab can significantly increase progression-free survival (PFS) in patients with advanced GC5. However, both the ATTRACTION-2 and CheckMate-032 trials indicated that the efficacy of immunotherapy in enhancing survival outcomes for GC patients appeared to be independent of PD-L1 expression status6,7.  \nIn this study, we performed a comprehensive analysis to assess the expression of P4HA3 in gastric cancer and explore its potential utility as a prognostic biomarker. Moreover, immunotherapy faces significant limitations, including a low response rate, a lack of robust predictive biomarkers, drug resistance, and toxicity8,9. Therefore, only a limited subset of patients with cancer achieve sustained clinical benefits from these therapies, thereby restricting their broader application10. This suggests the existence of additional immunotherapeutic biomarkers within the tumor microenvironment of gastric cancer. Identifying reliable immune-related biomarkers, such as  \n1Department of Oncology, Affiliated Hospital of North Sichuan Medical College, No. 1, Maoyuan South Road, Shunqing District, Nanchong City 637000, Sichuan Province, People’s Republic of China. 2North Sichuan Medical College, Nanchong, China. 3Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China. 4Yuanhang Yu, Kexin Luo and Meihan Liu contributed equally to this work. 􀀍 email:  \n[lixianfu13@163.com](lixianfu13@163.com)","cbCaimSukrPHWoOb","https://ap.wps.com/l/cbCaimSukrPHWoOb","pdf",5902676,15,"English","# Background and rationale\n## Immunotherapy and biomarker needs in gastric cancer\n# Study approach\n## Multi-database expression and association analysis\n# Key findings\n## Prognostic and diagnostic relevance of P4HA3\n## Links to immune infiltration and immune biomarkers\n# Biological context\n## ECM remodeling and collagen regulation by P4HA3","[{\"question\":\"What is P4HA3, and why is it studied in gastric cancer?\",\"answer\":\"P4HA3 (prolyl 4-hydroxylase subunit alpha 3) is described as a factor involved in proliferation, invasion, and metastasis in multiple tumors, but its role in gastric cancer needed further clarification.\"},{\"question\":\"How do the results relate P4HA3 to prognosis in gastric cancer?\",\"answer\":\"Higher P4HA3 expression in gastric cancer is associated with worse prognostic outcomes, indicating prognostic value.\"},{\"question\":\"What evidence connects P4HA3 to immunotherapy response?\",\"answer\":\"The analysis finds strong correlations between P4HA3 expression and immune infiltration cells, immune infiltration markers, TMB, MSI, immune/stromal scores, and immune checkpoints, supporting its potential as an immune-related predictive biomarker.\"}]","Comprehensive analysis reveals that P4HA3 is a prognostic and diagnostic gastric cancer biomarker that can predict immunotherapy efficacy | PDF",1790010582,38]